Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization
for heart failure and cardiovascular death among patients with chronic heart failure …

Background In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter 2 (SGLT2)
reduce the risk of a first hospitalization for heart failure, possibly through glucose-…

Background The angiotensin receptor–neprilysin inhibitor sacubitril–valsartan led to a
reduced risk of hospitalization for heart failure or death from cardiovascular causes among …

Background SGLT2 inhibitors are strongly recommended in guidelines to treat patients with
heart failure with reduced ejection fraction, but their clinical benefits at higher ejection …

Background Glucagon-like peptide-1 (GLP-1) receptor agonists differ in their structure and
duration of action and have been studied in trials of varying sizes and with different patient …

Whether the sodium–glucose cotransporter 2 inhibitor dapagliflozin reduces the risk of a
range of morbidity and mortality outcomes in patients with heart failure regardless of ejection …

Background Three drug classes (mineralocorticoid receptor antagonists [MRAs],
angiotensin receptor–neprilysin inhibitors [ARNIs], and sodium/glucose cotransporter 2 [SGLT2] …

Background— We examined whether population-level hospitalization rates for heart failure (HF)
and subsequent survival have continued to improve since the turn of the century. We …

Aims We tested the hypothesis that candesartan improves outcomes in heart failure (HF) with
mid‐range ejection fraction [HFmrEF; ejection fraction (EF) 40–49%]. Methods and results …

Heart failure (HF) and chronic obstructive pulmonary disease (COPD) are global epidemics
incurring significant morbidity and mortality. The combination presents many diagnostic …